Bull Flag Stocks
MDGL is forming a bull flag pattern, suggesting a potential continuation of its upward trend.
MADRIGAL PHARMACEUTICALS INC (MDGL) Stock Price & Overview
NASDAQ:MDGL • US5588681057
Current stock price
519.61 USD
-4.69 (-0.89%)
At close:
519.61 USD
0 (0%)
After Hours:
The current stock price of MDGL is 519.61 USD. Today MDGL is down by -0.89%. In the past month the price increased by 18.44%. In the past year, price increased by 63.84%.
MDGL Key Statistics
52-Week Range265 - 615
Current MDGL stock price positioned within its 52-week range.
1-Month Range427.76 - 572.195
Current MDGL stock price positioned within its 1-month range.
- Market Cap
- 11.92B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -12.75
- Dividend Yield
- N/A
MDGL Stock Performance
Today
-0.89%
1 Week
-4.99%
1 Month
+18.44%
3 Months
+1.08%
Longer-term
6 Months +20.95%
1 Year +63.84%
2 Years +154.69%
3 Years +66.54%
5 Years +281.78%
10 Years N/A
MDGL Stock Chart
MDGL Stock Screens
MDGL currently appears in the following ChartMill screener lists.
MDGL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MDGL. When comparing the yearly performance of all stocks, MDGL is one of the better performing stocks in the market, outperforming 83.64% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
MDGL Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MDGL. The financial health of MDGL is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
MDGL Earnings
On February 19, 2026 MDGL reported an EPS of -2.57 and a revenue of 321.08M. The company missed EPS expectations (-274% surprise) and beat revenue expectations (0.74% surprise).
Next Earnings DateApr 29, 2026
Last Earnings DateFeb 19, 2026
PeriodQ4 / 2025
EPS Reported-$2.57
Revenue Reported321.083M
EPS Surprise -274.00%
Revenue Surprise 0.74%
MDGL Forecast & Estimates
23 analysts have analysed MDGL and the average price target is 672.72 USD. This implies a price increase of 29.47% is expected in the next year compared to the current price of 519.61.
For the next year, analysts expect an EPS growth of 62.32% and a revenue growth 56.73% for MDGL
Analysts
Analysts81.74
Price Target672.72 (29.47%)
EPS Next Y62.32%
Revenue Next Year56.73%
MDGL Groups
Sector & Classification
MDGL Financial Highlights
Over the last trailing twelve months MDGL reported a non-GAAP Earnings per Share(EPS) of -12.75. The EPS increased by 42.33% compared to the year before.
Income Statements
Revenue(TTM)958.40M
Net Income(TTM)-288.28M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.89% | ||
| ROE | -47.83% | ||
| Debt/Equity | 0.56 |
Chartmill High Growth Momentum
EPS Q2Q%5.17%
Sales Q2Q%210.77%
EPS 1Y (TTM)42.33%
Revenue 1Y (TTM)432.05%
MDGL Ownership
Ownership
Inst Owners96.64%
Shares22.94M
Float21.16M
Ins Owners1.15%
Short Float %18.57%
Short Ratio10.6
MDGL Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MDGL
Company Profile
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Company Info
IPO: 2007-02-06
MADRIGAL PHARMACEUTICALS INC
200 Barr Harbor Drive, Suite 400
West Conshohocken PENNSYLVANIA 19428 US
CEO: Paul A. Friedman
Employees: 915
Phone: 14043809263
MADRIGAL PHARMACEUTICALS INC / MDGL FAQ
What does MADRIGAL PHARMACEUTICALS INC do?
Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania and currently employs 915 full-time employees. The company went IPO on 2007-02-06. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Can you provide the latest stock price for MADRIGAL PHARMACEUTICALS INC?
The current stock price of MDGL is 519.61 USD. The price decreased by -0.89% in the last trading session.
Does MDGL stock pay dividends?
MDGL does not pay a dividend.
What is the ChartMill rating of MADRIGAL PHARMACEUTICALS INC stock?
MDGL has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about MADRIGAL PHARMACEUTICALS INC (MDGL) stock?
23 analysts have analysed MDGL and the average price target is 672.72 USD. This implies a price increase of 29.47% is expected in the next year compared to the current price of 519.61.
What sector and industry does MADRIGAL PHARMACEUTICALS INC belong to?
MADRIGAL PHARMACEUTICALS INC (MDGL) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for MADRIGAL PHARMACEUTICALS INC?
MADRIGAL PHARMACEUTICALS INC (MDGL) has a market capitalization of 11.92B USD. This makes MDGL a Large Cap stock.